The Innovent deal adds 12 early-stage oncology assets—ADCs and multi-specifics—at a structured cost, diversifying pipeline risk beyond internally developed programs and Seagen assets. If several progress to Phase 3, Pfizer lengthens its late-decade growth runway without full upfront capital commitment.
the thesis · admitted · the reason above is the thesis, not printed twice
no findingread · nothing bore on it
It held on this filing. No finding was written because nothing in it bore on the reason — the sentences it was read against are below.
the evidence · every sentence checkedthree sentences · whole, uncut
the claims it rests on · in our words, not the filing’s